Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
Duodopa
Parkinson's disease
intrajejunal
levodopa/carbidopa intestinal gel
quality of life
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
18
02
2021
received:
15
07
2020
accepted:
05
03
2021
pubmed:
27
4
2021
medline:
1
9
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
Advanced Parkinson's disease is inconsistently defined, and evidence is lacking in relation to device-aided therapies. To update existing reviews of intrajejunal infusion of levodopa/carbidopa (LCIG), we performed a literature search for relevant articles (to November 3, 2020) using PubMed supplemented by hand searching. Retrieved articles were categorized by relevance to identified research questions, including motor complications and symptoms; nonmotor symptoms; functioning, quality of life, and caregiver burden; optimal timing of treatment initiation and administration duration; discontinuation; and complications. Most eligible studies (n = 56) were open-label, observational studies including relatively small patient numbers. LCIG consistently reduces OFF time and increased ON time without troublesome dyskinesia with varying effects regarding ON time with troublesome dyskinesia and the possibility of diphasic dyskinesia. More recent evidence provides some increased support for the benefits of LCIG in relation to nonmotor symptoms, quality of life, activities of daily living, and reduced caregiver burden. Patient age does not appear to significantly impact the effectiveness of LCIG. Discontinuation rates with LCIG (~17%-26%) commonly relate to device-related issues, although the ability to easily discontinue LCIG may represent a potential benefit. LCIG may be a favorable option for patients with advanced Parkinson's disease who show predominant nonmotor symptoms and vulnerability to complications of other advanced therapy modalities. Larger, well-controlled studies, including precise investigation of cost effectiveness, would further assist treatment selection. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 33899262
doi: 10.1002/mds.28595
pmc: PMC9290931
doi:
Substances chimiques
Antiparkinson Agents
0
Drug Combinations
0
Gels
0
Levodopa
46627O600J
Carbidopa
MNX7R8C5VO
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1759-1771Informations de copyright
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2011 Mar;26(4):664-70
pubmed: 21469197
J Neural Transm (Vienna). 2018 Aug;125(8):1299-1312
pubmed: 29511827
Front Neurol. 2018 Jul 30;9:620
pubmed: 30104997
Parkinsonism Relat Disord. 2011 Nov;17(9):693-7
pubmed: 21820940
J Neurol Sci. 2018 Feb 15;385:105-108
pubmed: 29406886
Parkinsonism Relat Disord. 2015 Jul;21(7):742-8
pubmed: 25962554
Parkinsonism Relat Disord. 2015 Aug;21(8):871-6
pubmed: 26003410
Ther Adv Neurol Disord. 2018 Feb 26;11:1756286418759315
pubmed: 29511383
Brain Behav. 2017 Jul 07;7(8):e00758
pubmed: 28828219
J Neurol. 2018 Jun;265(6):1279-1287
pubmed: 29557989
J Clin Neurosci. 2016 Mar;25:41-5
pubmed: 26777085
NPJ Parkinsons Dis. 2018 Nov 20;4:34
pubmed: 30480087
Mov Disord. 2017 Apr;32(4):624-625
pubmed: 28116835
Front Neurol. 2018 Apr 04;9:170
pubmed: 29670566
CNS Drugs. 2016 May;30(5):381-404
pubmed: 27138916
Mov Disord Clin Pract. 2018 Oct 25;5(5):542-545
pubmed: 30515445
Parkinsonism Relat Disord. 2020 Jul;76:98-103
pubmed: 31610986
Mov Disord Clin Pract. 2018 Jun 27;5(4):383-393
pubmed: 30363427
Adv Ther. 2017 Jul;34(7):1741-1752
pubmed: 28631218
Neurodegener Dis Manag. 2019 Feb;9(1):39-46
pubmed: 30547712
J Parkinsons Dis. 2014;4(3):517-21
pubmed: 24903924
NPJ Parkinsons Dis. 2018 Apr 17;4:12
pubmed: 29675463
Acta Neurol Scand. 2020 Sep;142(3):248-254
pubmed: 32383152
Mov Disord. 2016 Apr;31(4):530-7
pubmed: 26817533
J Parkinsons Dis. 2020;10(3):935-944
pubmed: 32675420
Drugs Aging. 2018 Dec;35(12):1041-1054
pubmed: 30318555
J Neurol. 2019 Sep;266(9):2164-2176
pubmed: 31134377
Parkinsonism Relat Disord. 2017 Apr;37:92-96
pubmed: 28063683
Eur Neurol. 2015;74(5-6):227-36
pubmed: 26618531
Mov Disord. 2019 Nov;34(11):1747-1748
pubmed: 31603586
J Neurol. 2018 Sep;265(9):2005-2014
pubmed: 29951701
Transl Neurodegener. 2017 May 26;6:14
pubmed: 28580139
Parkinsonism Relat Disord. 2017 Apr;37:79-86
pubmed: 28185758
Eur J Neurol. 2016 Mar;23(3):501-9
pubmed: 26498913
Eur J Neurol. 2019 Apr;26(4):581-e43
pubmed: 30353942
J Neurol. 2013 Nov;260(11):2701-14
pubmed: 23287972
J Neural Transm (Vienna). 2014 Jun;121(6):633-42
pubmed: 24398781
eNeurologicalSci. 2017 Jul 02;8:44-53
pubmed: 29260038
Acta Neurol Scand. 2019 Aug;140(2):157-161
pubmed: 31025312
Neuromodulation. 2014 Feb;17(2):126-32
pubmed: 24024760
J Parkinsons Dis. 2015;5(1):165-74
pubmed: 25588353
J Parkinsons Dis. 2018;8(3):409-420
pubmed: 30056433
Acta Neurol Scand. 2013 May;127(5):e28-32
pubmed: 23311399
Mov Disord Clin Pract. 2017 Nov-Dec;4(6):829-837
pubmed: 29242809
Lancet Neurol. 2014 Feb;13(2):141-9
pubmed: 24361112
Parkinsonism Relat Disord. 2019 Dec;69:140-146
pubmed: 31759188
Eur J Neurol. 2019 Mar;26(3):490-496
pubmed: 30347489
J Neurol. 2014 Mar;261(3):561-9
pubmed: 24477490
Parkinsons Dis. 2017;2017:4047392
pubmed: 28239501
Neuropsychiatr Dis Treat. 2020 Jul 28;16:1835-1844
pubmed: 32801718
J Neural Transm (Vienna). 2018 Aug;125(8):1131-1135
pubmed: 30006821
Clin Neuropharmacol. 2015 Jul-Aug;38(4):132-4
pubmed: 26166238
Drugs. 2019 Apr;79(6):593-608
pubmed: 30905034
Front Neurol. 2018 May 24;9:357
pubmed: 29881368
Front Neurol. 2018 Aug 27;9:697
pubmed: 30210429
J Parkinsons Dis. 2016 Jul 25;6(3):533-43
pubmed: 27472888
Acta Neurol Scand. 2018 Jul;138(1):78-84
pubmed: 29569237
Parkinsons Dis. 2013;2013:362908
pubmed: 23476888
Clin Neuropharmacol. 2017 May/Jun;40(3):103-107
pubmed: 28452905
Parkinsonism Relat Disord. 2017 Dec;45:13-20
pubmed: 29037498
Acta Neurol Scand. 2017 Dec;136(6):660-667
pubmed: 28608472
Eur J Neurol. 2014 Feb;21(2):312-8
pubmed: 24313838
Neuropsychiatr Dis Treat. 2008 Aug;4(4):743-57
pubmed: 19043519
J Parkinsons Dis. 2019;9(1):173-182
pubmed: 30562907
NPJ Parkinsons Dis. 2018 Jan 24;4:4
pubmed: 29387783
Mov Disord. 2018 Jul;33(6):928-936
pubmed: 29570853
J Neural Transm (Vienna). 2019 Jul;126(7):879-888
pubmed: 31222604
J Neurol. 2018 May;265(5):1124-1137
pubmed: 29516169
Parkinsonism Relat Disord. 2012 Sep;18(8):1000-1
pubmed: 22546333
Mov Disord. 2016 Apr;31(4):538-46
pubmed: 26695437
Eur Rev Med Pharmacol Sci. 2012 Jan;16(1):79-89
pubmed: 22338551
Iran J Neurol. 2017 Jul 6;16(3):118-124
pubmed: 29114366
Parkinsonism Relat Disord. 2016 Aug;29:104-8
pubmed: 27215392
J Neural Transm (Vienna). 2016 Apr;123(4):407-14
pubmed: 26699635
Parkinsonism Relat Disord. 2017 May;38:90-92
pubmed: 28238650
PLoS One. 2013 Jun 20;8(6):e66639
pubmed: 23818953
Curr Med Res Opin. 2012 Jul;28(7):1239-46
pubmed: 22686959
Parkinsons Dis. 2011 Mar 07;2011:472830
pubmed: 21437183
Acta Neurol Scand. 2012 Mar;125(3):187-91
pubmed: 21615352
J Parkinsons Dis. 2019;9(3):531-541
pubmed: 31282424